TransMedics Group, Inc. (TMDX) Current Ratio: 7.14
Is TransMedics Group, Inc.’s current ratio high or low?
TransMedics Group, Inc.'s current ratio of 7.14 is 19% below its 5-year average of 8.81, near the low end of its 5-year range (5.11–12.36).
As of Saturday, June 20, 2026. 7.51% below its 12-month average of 7.72.
TMDX Current Ratio Chart
TMDX Average Current Ratio Chart
TMDX Current vs Average Current Ratio Chart
TMDX Current Ratio Metrics
CURRENT RATIO
7.14
CURRENT RATIO AVG TTM
7.72
CURRENT RATIO AVG 3Y
8.85
CURRENT RATIO AVG 5Y
8.81
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-7.51%
CURRENT VS 3Y AVG
-19.32%
CURRENT VS 5Y AVG
-18.97%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 7.14 | 7.72 | 8.85 | 8.81 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 1.51 | 1.31 | 1.40 | 1.40 |
| 23andMe Holding Co. (ME)vs › | $15.31M | 0.83 | 1.40 | 2.39 | 2.32 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 5.62 | 6.05 | 5.87 | 4.96 |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 1.90 | 1.84 | 2.80 | 3.67 |
| Tempus AI, Inc. (TEM)vs › | $8.87B | 3.13 | 2.71 | 2.36 | 3.23 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 1.29 | 1.35 | 1.39 | 1.37 |
| Baxter International Inc. (BAX)vs › | $10.27B | 2.31 | 1.83 | 1.71 | 1.91 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.68 | 0.66 | 0.70 | 0.70 |
| Revvity, Inc. (RVTY)vs › | $11.16B | 1.68 | 2.64 | 2.37 | 2.14 |
Liquidity Analysis
Current Ratio
7.14
Quick Ratio
6.59
TransMedics Group, Inc. Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Current Ratio FAQ
- What is the current ratio for TransMedics Group, Inc. (TMDX)?
- The current ratio for TMDX stock is 7.14.
- Is TransMedics Group, Inc.'s current ratio high or low?
- TransMedics Group, Inc.'s current ratio of 7.14 is 19% below its 5-year average of 8.81, near the low end of its 5-year range (5.11–12.36).
- What is the TTM average current ratio for TransMedics Group, Inc. (TMDX)?
- The TTM average current ratio for TMDX stock is 7.72.
- What is the 3Y average current ratio for TransMedics Group, Inc. (TMDX)?
- The 3Y average current ratio for TMDX stock is 8.85.
- What is the 5Y average current ratio for TransMedics Group, Inc. (TMDX)?
- The 5Y average current ratio for TMDX stock is 8.81.
TransMedics Group, Inc. Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 7.14 |
| 2024-12-31 | 8.30 |
| 2023-12-31 | 9.30 |
| 2022-12-31 | 10.66 |
| 2021-12-31 | 5.11 |
| 2020-12-31 | 12.36 |
| 2019-12-31 | 6.21 |
| 2018-12-31 | 2.77 |
| 2017-12-31 | 3.12 |
| 2016-12-31 | 5.90 |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein